Zepbound vs Trulicity: Head-to-Head Efficacy Compared

Mechanism of Action: One Receptor vs Two

Tirzepatide, the active molecule in Zepbound, is the first FDA-approved dual GIP and GLP-1 receptor agonist. It binds both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, producing additive effects on insulin secretion, appetite suppression, and fat metabolism [1]. The GIP pathway may also reduce fat storage independently of GLP-1 signaling, according to preclinical data published in Cell Metabolism [2].

Dulaglutide (Trulicity) is a selective GLP-1 receptor agonist. It uses a large Fc-fused construct that extends its half-life to approximately five days, supporting once-weekly dosing [3]. That single-receptor approach was the standard of care for incretin therapy from 2014 through 2022.

The practical implication is straightforward. Dual-receptor activation appears to produce greater reductions in body weight and HbA1c than GLP-1-only agonists, a pattern confirmed across the SURPASS and SURMOUNT trial programs [1]. Whether that translates into better long-term cardiovascular protection remains an open question because Zepbound lacks a completed cardiovascular outcomes trial (CVOT).

Weight Loss: SURMOUNT-1 vs AWARD and REWIND Data

Zepbound's weight-loss efficacy comes primarily from SURMOUNT-1, a phase 3 trial of 2,539 adults with obesity or overweight (BMI ≥30, or ≥27 with at least one weight-related comorbidity) but without type 2 diabetes. At the highest dose of 15 mg, participants lost a mean of 20.9% of their body weight over 72 weeks, compared with 3.1% in the placebo arm (P<0.001) [1]. The 10 mg arm produced 19.5% loss, and the 5 mg arm produced 15.0% loss. Those numbers placed tirzepatide well ahead of every other injectable GLP-1 agonist tested in obesity at the time.

Trulicity was never designed as a weight-loss drug. Its key AWARD trial program studied dulaglutide in type 2 diabetes. AWARD-1 reported mean weight reductions of 1.30 kg (0.75 mg) and 2.90 kg (1.5 mg) versus exenatide over 52 weeks [3]. REWIND, the large cardiovascular outcomes trial (N=9,901), showed a modest 2.95 kg mean reduction at 1.5 mg over a median follow-up of 5.4 years [4]. The 4.5 mg dose, approved later, showed approximately 4.6 kg loss in a 36-week study, still well below tirzepatide's range [5].

A cross-trial comparison demands caution because populations, endpoints, and follow-up durations differ. SURMOUNT-1 enrolled people without diabetes; REWIND enrolled people with established or high-risk type 2 diabetes. Baseline BMI differed by several points. Still, the magnitude gap is large enough that most endocrinologists consider tirzepatide the stronger weight-loss agent. Dr. Ania Jastreboff, principal investigator of SURMOUNT-1, stated: "The degree of weight reduction observed with tirzepatide is unprecedented for a non-surgical intervention" [1].

Glycemic Control: SURPASS vs AWARD Programs

For patients with type 2 diabetes, both drugs lower HbA1c, but tirzepatide (branded as Mounjaro for T2D, same molecule as Zepbound) has shown larger reductions. In SURPASS-2, tirzepatide 15 mg reduced HbA1c by 2.46% from a baseline of approximately 8.3%, while semaglutide 1 mg reduced it by 1.86% (P<0.001 for superiority) [6]. Because semaglutide 1 mg is more potent than dulaglutide 1.5 mg in glycemic trials, the implied advantage of tirzepatide over dulaglutide is even wider.

Trulicity's AWARD-11 trial tested the higher 3.0 mg and 4.5 mg doses against the established 1.5 mg dose. The 4.5 mg arm achieved a 1.87% HbA1c reduction from baseline (mean 8.6%) at 36 weeks [5]. That figure falls roughly 0.6 percentage points below tirzepatide 15 mg in SURPASS-2, although again, direct comparison requires caution.

One area where Trulicity holds a clear data advantage is in cardiovascular outcome evidence. No CVOT for tirzepatide has yet reported primary results. SURPASS-CVOT (NCT04255433) is ongoing, with an estimated completion date in 2025. Until those results are published, Trulicity's REWIND data remains uniquely valuable for patients whose primary concern is cardiovascular risk reduction [4].

Cardiovascular Outcomes: REWIND Sets Trulicity Apart

REWIND enrolled 9,901 adults with type 2 diabetes, 31% of whom had established cardiovascular disease at baseline. Over a median follow-up of 5.4 years, dulaglutide 1.5 mg reduced the composite MACE endpoint (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) by 12% compared with placebo (HR 0.88, 95% CI 0.79 to 0.99; P=0.026) [4].

That result is clinically meaningful. The American Diabetes Association (ADA) 2024 Standards of Care recommend GLP-1 receptor agonists with proven cardiovascular benefit for patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), and dulaglutide is on that list [7]. Tirzepatide is not yet included in that specific recommendation because its CVOT has not completed.

Dr. Hertzel Gerstein, REWIND's lead investigator, noted: "REWIND showed cardiovascular benefit in a broad population of people with type 2 diabetes, including those with and without prior cardiovascular events" [4]. That broad applicability gives Trulicity a clinical niche that Zepbound cannot yet fill with the same level of evidence.

For a patient whose primary goal is weight reduction and who does not have established ASCVD, the cardiovascular data gap may matter less. For a patient with a prior MI or stroke and concurrent type 2 diabetes, prescribing a GLP-1 agonist with proven MACE reduction carries a different clinical weight. This distinction shapes real-world prescribing decisions daily.

Dosing, Titration, and Administration

Both medications are administered as once-weekly subcutaneous injections using autoinjector pens. The titration schedules differ in pace and ceiling.

Zepbound starts at 2.5 mg weekly for four weeks, then increases to 5 mg. Further escalation to 10 mg and then 15 mg occurs in 2.5 mg increments at minimum four-week intervals, based on tolerability and clinical response [8]. The slower titration is designed to limit GI side effects, which are most common during dose escalation.

Trulicity starts at 0.75 mg weekly. If additional glycemic control is needed after four weeks, the dose increases to 1.5 mg. The 3.0 mg and 4.5 mg doses are available for patients requiring more aggressive A1C lowering [9]. The step-up is faster than Zepbound's because the total dose range is narrower.

Both pens require refrigeration before first use and can be kept at room temperature (up to 30°C / 86°F) for a limited period. Neither requires reconstitution. Injection sites include the abdomen, thigh, or upper arm, with site rotation recommended.

Side Effect Profile: What to Expect

Gastrointestinal events dominate both drugs' adverse-effect profiles. Nausea, diarrhea, vomiting, constipation, and decreased appetite are the most commonly reported treatment-emergent events in trials of both tirzepatide and dulaglutide [1][3].

In SURMOUNT-1, nausea occurred in 24.6% of participants on tirzepatide 5 mg and 33.3% on 15 mg, compared with 9.5% on placebo. Diarrhea rates were 18.7% (5 mg) and 21.1% (15 mg) versus 7.3% placebo. Most GI events were mild to moderate and peaked during the dose-escalation phase [1].

In AWARD-1, nausea occurred in 17.8% (0.75 mg) and 26.1% (1.5 mg) of dulaglutide-treated participants. Diarrhea rates were 12.4% and 14.3%, respectively [3]. At the higher 4.5 mg dose tested in AWARD-11, GI side effects increased modestly [5].

Both drugs carry warnings about the theoretical risk of medullary thyroid carcinoma based on rodent studies. The FDA labeling for each includes a boxed warning contraindicating their use in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 [8][9].

Pancreatitis has been reported rarely with both agents. Gallbladder-related events (cholelithiasis, cholecystitis) occur more frequently with tirzepatide, likely related to the rapid weight loss it produces. In SURMOUNT-1, cholelithiasis was reported in 0.6% of tirzepatide-treated participants versus 0.1% on placebo [1].

Cost, Insurance, and Access Considerations

List prices for both drugs are high, though Trulicity's longer market history has created a broader payer coverage footprint. Zepbound's wholesale acquisition cost (WAC) is approximately $1,059.87 per month. Trulicity's WAC is roughly $990, $1,100 per month depending on dose, but generic dulaglutide is not yet available in the U.S. as of early 2026 [10].

Insurance coverage differs significantly by indication. Trulicity is covered by most commercial plans and Medicare Part D for type 2 diabetes management. Zepbound is FDA-approved only for chronic weight management, and many insurers exclude or restrict anti-obesity medications from formularies [10].

For patients with type 2 diabetes, the tirzepatide molecule is available under the Mounjaro brand name, which has its own coverage pathways. Clinicians sometimes prescribe Mounjaro for T2D when they want the dual-agonist mechanism, then separately consider Zepbound if the patient's primary indication shifts to weight management. The payer dynamics are complex and plan-specific.

Manufacturer savings cards can reduce out-of-pocket costs for commercially insured patients. Eli Lilly offers programs for both Zepbound and Mounjaro. For Trulicity, the savings card program lowers copays for eligible patients, though terms vary.

Who Should Consider Which Drug?

Selecting between these agents depends on the clinical goal, the patient's comorbidity profile, and insurance access.

Zepbound fits best for patients whose primary treatment goal is substantial weight reduction, who have a BMI ≥30 (or ≥27 with a weight-related condition), and who can access the medication through insurance or self-pay. Its 15 to 21% body-weight reduction in trials exceeds what any single-agonist GLP-1 medication has achieved [1].

Trulicity fits best for patients with type 2 diabetes who need proven cardiovascular risk reduction, particularly those with established ASCVD. The REWIND data showing 12% MACE reduction is a differentiator that no amount of cross-trial weight-loss comparison can replace [4]. Trulicity is also a practical choice when formulary access to tirzepatide products is restricted.

Some patients may benefit from starting on Trulicity for glycemic and cardiovascular management and later switching to a tirzepatide-based product if weight loss becomes a greater priority. Others might start with Zepbound for weight management and transition if cardiovascular data for tirzepatide becomes available through SURPASS-CVOT.

Switching Between Agents: Clinical Guidance

No published randomized trial has studied direct switching from Zepbound to Trulicity or vice versa. In clinical practice, switches between GLP-1 receptor agonists are common and generally handled by stopping one agent and starting the other at the initial titration dose, without a washout period.

The 2024 ADA Standards of Care do not specify a mandatory wash-out between incretin-based therapies [7]. Most endocrinologists restart the new drug at its lowest dose to assess tolerability, even if the patient was on a high dose of the prior agent. GI side effects may recur during the transition, particularly if the new agent has a different receptor profile.

Patients switching from Zepbound (dual GIP/GLP-1 agonist) to Trulicity (GLP-1 only) should be counseled that weight regain is possible because the GIP-mediated effects will be lost. Patients moving in the other direction, from Trulicity to Zepbound, should be titrated slowly through Zepbound's dose ladder and monitored for GI tolerability.

The SURPASS-CVOT Gap: What We Know and Don't Know

SURPASS-CVOT (NCT04255433) is a phase 3 trial designed to evaluate tirzepatide's effect on major cardiovascular events in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. The trial enrolled approximately 13,500 participants and is expected to report results in late 2025 or early 2026 [11].

If SURPASS-CVOT demonstrates MACE reduction comparable to or exceeding REWIND's 12% HR reduction, the clinical calculus shifts substantially in favor of tirzepatide across nearly every patient subgroup. The ADA would likely update its recommendations to include tirzepatide among preferred agents for cardiovascular risk reduction. Until that data is published and peer-reviewed, prescribers must rely on REWIND for cardiovascular outcome evidence.

The absence of CVOT data for tirzepatide does not mean the drug is cardiovascularly unsafe. SURMOUNT-1 and the SURPASS program showed no cardiovascular safety signals, and tirzepatide's FDA approval included a standard cardiovascular safety assessment [1][6]. The distinction is between demonstrated safety and demonstrated benefit.

Clinicians treating patients with both obesity and high cardiovascular risk often face this exact tension: choose the stronger weight-loss agent (Zepbound) or choose the agent with proven MACE reduction (Trulicity). Until SURPASS-CVOT reports, there is no evidence-based way to resolve that tension completely. The decision rests on which risk factor the clinician and patient prioritize.